Cytokinetics, IncorporatedCYTK
NasdaqGS•Healthcare•Biotechnology
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics, Incorporated (CYTK) reported trailing twelve months revenue of $105.81M as of March 2026, a 450.6% increase year-over-year. Quarterly revenue reached $19.36M, reflecting continued top-line momentum.
Cytokinetics, Incorporated reported a TTM net loss of $829.61M, with quarterly EBITDA of $-180.24M. The operating margin expanded from -9856.3% to -948.7%, suggesting improving cost efficiency and pricing discipline.
The spread between operating margin (-948.7%) and net margin (-1064.5%) indicates significant non-operating expenses or interest burden. Net margin has improved from -10220.1% a year ago, signaling stronger bottom-line efficiency.
CYTK trades at a P/S of 0.1x.
The company reported negative free cash flow of $-151.39M, indicating cash consumption over the period. The balance sheet shows $1.27B in total assets with $247.21M in long-term debt against $-826.57M in stockholders equity. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are under pressure, averaging -13012.5%. The business may lack pricing power or face rising costs.'
Limited ROE data for a reliable assessment.
Only 0 of the last 8 quarters had positive FCF — the business may require external capital to sustain operations.
TTM revenue has grown consistently (7 of 7 quarters up), with ~3276.4% growth over the period. Strong demand durability.
Data-driven red flags and warnings across 21 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
Limited debt-to-equity data available.
Revenue is stable or growing over recent quarters — demand appears durable.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares outstanding increased 12.8% — significant dilution, likely from stock compensation or capital raises.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation